Cartalax vs bpc-157

updated October 25, 2026

Cartalax (tier C) vs bpc-157 (tier A): what each is, why each got its grade, half-life and source counts side by side.

Cartalax · tier C

an identity-gated Ala-Glu-Asp tripeptide with cell and animal work plus one poorly reported, 29-person saline-controlled human example in an assignee patent, but no independent peer-reviewed replication or measured pharmacokinetic curve.

tier rationale

C-tier applies only to identity-verified synthetic L-Ala-L-Glu-L-Asp. The molecule is defined, has cell and animal observations, and has sparse human evidence in a poorly reported 29-person saline-controlled assignee-patent example. It cannot grade higher because the patent omits important design, group-level outcome, and safety detail; no independent peer-reviewed replication, formal pharmacokinetic study, independent toxicology package, or regulator-reviewed product was located. A product with unresolved sequence or extract composition does not inherit this grade.

bpc-157 · tier A

the contested repair peptide. strong animal data, thin human trials, huge community gravity.

tier rationale

A-tier because the preclinical evidence is extraordinary and the community signal is persistent. Not S-tier because drug-grade human evidence does not exist, long-term human safety is not characterized, and the single-lab concentration matters. If independent controlled trials ever hold up, the tier can move. Until then, A is the ceiling.

at a glance

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.